Paul Audhya
Chief Tech/Sci/R&D Officer chez KALVISTA PHARMACEUTICALS, INC.
Fortune : 627 228 $ au 31/03/2024
Profil
Paul K.
Audhya is currently the Chief Medical Officer at KalVista Pharmaceuticals, Inc. He was previously the Senior Vice President-Medical Affairs at Arena Pharmaceuticals, Inc. from 2018 to 2021, the VP-Global Strategy & Medical Affairs at Vertex Pharmaceuticals, Inc. from 2016 to 2018, and the Vice President-Medical Affairs at Hospira, Inc. from 2013 to 2016.
He also served as the Chief Medical Officer & Vice President-Development at Reata Pharmaceuticals, Inc. Dr. Audhya received his undergraduate degree from New York University in 1993, his doctorate from New York University in 1997, and his MBA from Pepperdine University in 2010.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/02/2024 | 52 886 ( 0,13% ) | 627 228 $ | 31/03/2024 |
Postes actifs de Paul Audhya
| Sociétés | Poste | Début |
|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 03/05/2021 |
Anciens postes connus de Paul Audhya
| Sociétés | Poste | Fin |
|---|---|---|
| ARENA PHARMACEUTICALS | Corporate Officer/Principal | 01/03/2021 |
| VERTEX PHARMACEUTICALS INCORPORATED | Chief Tech/Sci/R&D Officer | 01/09/2018 |
| HOSPIRA, INC. | Chief Tech/Sci/R&D Officer | 01/02/2016 |
| REATA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Paul Audhya
| New York University | Undergraduate Degree |
| Pepperdine University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Hospira, Inc.
 Hospira, Inc. Pharmaceuticals: MajorHealth Technology Hospira, Inc. provides injectable drugs and infusion technologies. It offers drugs, IV sets and clinical integration, infusion pumps, clinical software and implementation services. The company was founded on September 16, 2003 and is headquartered in Lake Forest, IL. | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
